Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

FEATURES OF Emerging Cancer Therapeutics INCLUDE:

• Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics
• In-depth, up-to-date expert reviews and analysis of major new developments in all areas
• of Cancer Therapeutics
• Issues edited by an authority in specific subject area
• Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience

FORTHCOMING ISSUES IN Emerging Cancer Therapeutics VOLUME 2, 2011

Renal Cancer, Issue 1, 2011: Walter Stadler, MD, University of Chicago
Leukemia, Issue 2, 2011: Uday Popat, MD, MD Anderson Cancer Center